The Global Health Body Sounds Concern Over Acute Scarcity of Weight-Loss Medications

Fewer than a tenth of patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, states the World Health Organization as it publishes its first advice on the drugs.

With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging increased and just availability to this class of drugs.

Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.

"Our latest guidelines recognises that excess weight is a lifelong illness that can be treated with thorough and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are significant obstacles to universal availability to the injections that can help people shift considerable weight, says the organization.

GLP-1 Therapy Shortage

Even under the present most favorable scenario, the supply of GLP-1 therapies might only reach about 100 million people – less than 10% of eligible patients, as stated by the WHO.

The recommendation calls on governments and firms to increase access, through strategies like patent sharing.

The intellectual property rights on semaglutide – the main component of a leading brand – is set to lapse in a number of nations in 2026.

The Way Obesity Drugs Operate

The injections imitate a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so individuals consume fewer calories.

Individuals typically begin shedding pounds within a few weeks of commencing the regular doses.

Studies points to users may regain a significant portion a year later of stopping the medication, because their typical food cravings come back.

To be carrying excess weight increases your risk for developing diseases, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.

Obesity impacts people in every country and was associated with millions of fatalities worldwide in 2024, as per the health agency.